Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trial

Latigo Biotherapeutics reported financial results for the third quarter ended September 30, 2026, on November 5, 2026, alongside pipeline and leadership updates. The company said its randomized, double-blind, placebo- and active-controlled Phase 3 clinical trial in patients with moderate-to-severe acute pain after bunionectomy surgery, along with a single-arm, open-label Phase 3 safety trial, remain on track to start, with topline results expected in the second half of 2027.¹

Latigo said it intends to update the bunionectomy trial design by adding an active opioid comparator arm using oxycodone/acetaminophen, commonly known as Percocet, to supplement data supporting opioid-sparing label claims, comparing it against a more potent opioid than the hydrocodone/acetaminophen comparator (commonly known as Vicodin) used in the abdominoplasty trial.¹ The company noted that Percocet is 1.5 times as strong as Vicodin according to U.S. Centers for Disease Control guidelines.¹ The redesigned trial is expected to enroll approximately 480 patients, with about 200 receiving onzotrigine (450 mg loading dose followed by 300 mg twice daily), 80 receiving oxycodone/acetaminophen (5 mg/325 mg), and about 200 receiving placebo.¹

For LTG-321, Latigo's chronic pain candidate, the company said its Phase 2 randomized, double-blind, placebo-controlled, within-patient crossover trial is ongoing and will enroll approximately 120 patients with osteoarthritis of the knee, evaluating safety and efficacy of once-daily dosing¹, with topline results expected in the second half of 2027.¹

On cash, the company reported cash and cash equivalents of $401.2 million as of September 30, 2026, which it said are expected to fund current operating plans into 2029.¹

Separately, the company disclosed that effective November 3, 2026, the Board approved the appointment of Todd Smith as President and Chief Executive Officer, replacing Nima Farzan in those roles.¹ Farzan's resignation from the Board was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.¹